Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
DVAX Dynavax Technologies
11.825+0.425+3.73%
Trading Session
02/02 12:41 ET
High
11.930
Open
11.530
Turnover
8.01M
Low
11.490
Pre Close
11.400
Volume
682.15K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Dynavax Announces Uplisting to the Nasdaq Global Select Market
EMERYVILLE, Calif., Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a Bet
Comerica Bank Sells 9,855 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
Comerica Bank lowered its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 10.4% in the third quarter, according to the company in its most recent disclosure with the Sec
Short Interest in Dynavax Technologies Co. (NASDAQ:DVAX) Drops By 7.2%
Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) was the recipient of a large decrease in short interest during the month of December. As of December 30th, there was short interest totalling 12,80
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Weyerhaeuser Co (NYSE:WY) a lot. When asked about Lockheed Martin Corp (NYSE:LMT), he said, "People are worried about the Republicans
New York State Teachers Retirement System Buys 18,470 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
New York State Teachers Retirement System raised its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 14.5% during the 3rd quarter, according to the company in its most recent 13F fil
Dynavax Technologies (NASDAQ:DVAX) Shareholder Returns Have Been Respectable, Earning 88% in 3 Years
By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, the Dynavax Technologies C
Q4 2022 EPS Estimates for Dynavax Technologies Co. Increased by HC Wainwright (NASDAQ:DVAX)
Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) – Analysts at HC Wainwright lifted their Q4 2022 earnings per share (EPS) estimates for Dynavax Technologies in a research note issued to investo
Gables Capital Management Inc. Lowers Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)
Gables Capital Management Inc. decreased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 11.1% in the 3rd quarter, according to the company in its most recent Form 13F filing
Dynavax Technologies' Preliminary Q4, Full-Year 2022 Revenue for Heplisav-B and CpG 1018 Show Gains
09:05 AM EST, 01/09/2023 (MT Newswires) -- Dynavax Technologies (DVAX) said Monday preliminary Q4 and full-year 2022 revenue for its hepatitis B vaccine Heplisav-B was about $35 million and $126 milli
Company Overview
More
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
CEO： Mr. Ryan Spencer
Market： NASDAQ
Listing Date： 02/19/2004
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet